Objective:To evaluate the current approaches for multimodality therapy for stage ⅠB cervical cancer.Methods:The relevant literature has served as a source for identified high or intermediate risks and management of s...Objective:To evaluate the current approaches for multimodality therapy for stage ⅠB cervical cancer.Methods:The relevant literature has served as a source for identified high or intermediate risks and management of stage ⅠB cervical cancer.Result:The high risks include pelvic lymph node metastasis(PLNM),positive resection margin(PRM),and the involvement of parametrium(IPM).The intermediate risks include deep stromal invasion(DSI),bulky tumor size(BTS),lymphovascular space invasion(LVSI).Adeno-carcinomatous histotype is the new risk feature relevant to poor prognoses.Both radical hysterectomy plus bilateral pelvic lymph node dissection(PLND) and radical radiotherapy have proven to be equally effective.Surgery is more performed for stage ⅠB1 disease;radiotherapy or chemoradiotherapy is preferable for stage ⅠB2 disease.For patients with one high risk or two of intermediate risks,radical hysterectomy plus PLND followed by concurrent chemoradiotherapy can improve overall survival(OS) and disease-free survival(DFS).Conclusion:The management should be individualized for stage ⅠB cervical cancer.The optimized multidisciplinary therapy can benefit patients with the best cure and minimum morbidity and complications.展开更多
Objective:To evaluate the toxicity of paclitaxel and cisplatin combination in patients with advanced ovarian cancer.Methods:A retrospective review was performed on patients with stage Ⅲ or stage Ⅳ ovarian cancer tre...Objective:To evaluate the toxicity of paclitaxel and cisplatin combination in patients with advanced ovarian cancer.Methods:A retrospective review was performed on patients with stage Ⅲ or stage Ⅳ ovarian cancer treated in QiLu hospital between October 1996 and June 1999 Results:26 patients received adjuvant paclitaxel and cisplatin chemotherapy.The significant toxicity included:anemia 7/26(27%),thrombocytopenia 10/26(38%),neutropenia 19/26(73%),nausea or vomiting 24/26(92%) and neurotoxicity 11/26(42%).No patient delayed.No patient died during treatment.Conclusion:The dosages of primary paclitaxel and cisplatin chemotherapy is reasonably well tolerated for patients with stage Ⅲ or Ⅳ ovarian cancer.展开更多
文摘Objective:To evaluate the current approaches for multimodality therapy for stage ⅠB cervical cancer.Methods:The relevant literature has served as a source for identified high or intermediate risks and management of stage ⅠB cervical cancer.Result:The high risks include pelvic lymph node metastasis(PLNM),positive resection margin(PRM),and the involvement of parametrium(IPM).The intermediate risks include deep stromal invasion(DSI),bulky tumor size(BTS),lymphovascular space invasion(LVSI).Adeno-carcinomatous histotype is the new risk feature relevant to poor prognoses.Both radical hysterectomy plus bilateral pelvic lymph node dissection(PLND) and radical radiotherapy have proven to be equally effective.Surgery is more performed for stage ⅠB1 disease;radiotherapy or chemoradiotherapy is preferable for stage ⅠB2 disease.For patients with one high risk or two of intermediate risks,radical hysterectomy plus PLND followed by concurrent chemoradiotherapy can improve overall survival(OS) and disease-free survival(DFS).Conclusion:The management should be individualized for stage ⅠB cervical cancer.The optimized multidisciplinary therapy can benefit patients with the best cure and minimum morbidity and complications.
文摘Objective:To evaluate the toxicity of paclitaxel and cisplatin combination in patients with advanced ovarian cancer.Methods:A retrospective review was performed on patients with stage Ⅲ or stage Ⅳ ovarian cancer treated in QiLu hospital between October 1996 and June 1999 Results:26 patients received adjuvant paclitaxel and cisplatin chemotherapy.The significant toxicity included:anemia 7/26(27%),thrombocytopenia 10/26(38%),neutropenia 19/26(73%),nausea or vomiting 24/26(92%) and neurotoxicity 11/26(42%).No patient delayed.No patient died during treatment.Conclusion:The dosages of primary paclitaxel and cisplatin chemotherapy is reasonably well tolerated for patients with stage Ⅲ or Ⅳ ovarian cancer.
